Replies to post #35521 on Sunshine Biopharma Inc (SBFM)

[General Grievous]

Cuz it's all smoke and mirrors

[KrazyQuestors]

Also they never get their DIN number for the drug from Health Canada only BS

[Adam16]

I BELIEVE THE REPORT INCLUDES THESE ALSO? These numbers are sec reported I believe


 
?

Arimidex® $232M in 2016

?

Femara® $380M in 2014

?

Casodex® $247M in 2016

?

Propecia® $183M in 2015

 

Sunshine Canada is currently in the process of securing a Drug Identification Number (“DIN”) for each of these products from Health Canada. We are also working on finding an appropriate facility and obtaining a Drug Establishment License (“DEL”) from Health Canada. Upon receipt of the DEL and DIN’s, we will be able to accept orders for our own label SBI-Anastrozole, SBI-Letrozole, SBI-Bicalutamide and SBI-Finasteride. We cannot estimate the timing in our obtaining either the DIN or DEL due to variables involved that are out of our control. The Figure below shows our 30-Pill blister pack of Anastrozole

[skichic]

This is why:
Adva-27a, the Company's flagship anticancer compound. A Topoisomerase II inhibitor, Adva-27a is a small molecule that has recently been shown to be effective at destroying Multidrug Resistant Breast Cancer cells, Pancreatic Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Sunshine Biopharma is direct owner of all issued and pending worldwide patents pertaining to Adva-27a including U.S. Patent Number 8,236,935.

[Slydogg27]

http://www.in-pharmatechnologist.com/Ingredients/Lonza-set-to-get-commercial-Adva-27a-contract-if-cancer-drug-is-approved


http://sunshinebiopharma.com/adva-27a-anticancer-drug.html

Our flagship anticancer compound is Adva-27a, a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer (See 3D Molecular Model below). Adva-27a is expected to enter Phase I clinical trials for pancreatic cancer and multidrug resistant breast following completion of the GMP manufacturing and formulation of a 2-kilograms quantity for injection. The mechanism by which Adva-27a is able to destroy cancer cells is through the inhibition of a key cell-cycle enzyme called Topoisomerase II. Unlike other antitumor drugs currently in use, Adva-27a is able to destroy multidrug resistant cancer cells. Adva-27a is very effective against multidrug resistant breast cancer cells while Etoposide, another Topoisomerase II inhibitor, has no activity against this aggressive form of cancer (see Figure below). In other studies, Adva-27a showed cell killing activity in various other types of multidrug resistant cancer cells. Our preclinical studies to date have shown that:





Sunshine Biopharma Is Moving Forward With Its Development Plans ...
www.marketwired.com/.../sunshine-biopharma-is-moving-forward-with-its-developm...
Jan 20, 2016 - The Company is planning Phase I clinical trials of Adva-27a on Pancreatic Cancer and, in parallel, Multidrug Resistant Breast Cancer patient ...